Artwork
iconShare
 
Manage episode 501694798 series 3599769
Content provided by Ontada Learn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ontada Learn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode of OncoTalks, Dr. Paul Conkling and Dr. Kashif Ali explore how minimal residual disease (MRD) testing using circulating tumor DNA (ctDNA) is reshaping breast cancer management. They discuss how this innovative approach enables the detection of molecular disease that may persist after treatment — often before clinical or radiographic signs appear. Research shows MRD testing can identify recurrence months earlier than conventional methods, allowing for timely intervention and more informed decision-making. As a result, MRD testing is becoming an increasingly valuable tool in personalized cancer care.

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

  continue reading

17 episodes